Coronary β 2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: Novel insights from an in vivo intravascular ultrasound study

European Heart Journal

Volumn 33, Issue 4, 2012, Pages 495-504

  Puri, Rishi ^a   Liew, Gary Y H ^a,b   Nicholls, Stephen J ^c   Nelson, Adam J ^a   Leong, Darryl P ^a   Carbone, Angelo ^a   Copus, Barbara ^b   Wong, Dennis T L ^a   Beltrame, John F ^a,d   Worthley, Stephen G ^a,b   Worthley, Matthew I ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

2 adrenoreceptors; atherosclerosis; endothelial function; IVUS; salbutamol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; N(G) METHYLARGININE; NITRIC OXIDE; SALBUTAMOL;

ADRENERGIC SYSTEM; ADULT; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; IN VIVO STUDY; INTRAVASCULAR ULTRASOUND; MALE; PRIORITY JOURNAL; STIMULUS RESPONSE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MICROCIRCULATION; MICROVASCULAR ANGINA; MIDDLE AGED; NITRIC OXIDE; OBSERVER VARIATION; OMEGA-N-METHYLARGININE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, ADRENERGIC, BETA-2; ULTRASONOGRAPHY, INTERVENTIONAL; VASODILATOR AGENTS;

EID: 84857183589     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr359     Document Type: Article

References (44)

1. Barbato E. Role of adrenergic receptors in human coronary vasomotion. Heart 2009;95:603-608.
2. Braun OO, Insel PA. The best 'model system' for human (coronary arteries) is human. J Am Coll Cardiol 2009;54:1146-1148.
3. Ferro A, Queen LR, Priest RM, Xu B, Ritter JM, Poston L, Ward JP. Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol 1999;126:1872-1880. (Pubitemid 29213107)
4. Bea ML, Ghaleh B, Giudicelli JF, Berdeaux A. Lack of importance of NO in beta-adrenoceptor-mediated relaxation of large epicardial canine coronary arteries. Br J Pharmacol 1994;111:981-982.
5. Macdonald PS, Dubbin PN, Dusting GJ. Beta-adrenoceptors on endothelial cells do not influence release of relaxing factor in dog coronary arteries. Clin Exp Pharmacol Physiol 1987;14:525-534. (Pubitemid 18008599)
6. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954. (Pubitemid 30131694)
7. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906. (Pubitemid 30225269)
8. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658. (Pubitemid 34851922)
9. Lavi S, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, Holmes DR Jr, Lerman A. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart 2009;95: 1525-1530.
10. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994;90:5-11. (Pubitemid 24203655)
11. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010;55:2399-2407.
12. Barbato E, Piscione F, Bartunek J, Galasso G, Cirillo P, De Luca G, Iaccarino G De Bruyne B, Chiariello M, Wijns W. Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation 2005;111:288-294. (Pubitemid 40165334)
13. Anderson TJ, Worthley MI, Goodhart DM, Curtis MJ. Relation of Basal coronary nitric oxide activity to the burden of atherosclerosis. Am J Cardiol 2005;95: 1170-1174. (Pubitemid 40616418)
14. Seddon M, Melikian N, Dworakowski R, Shabeeh H, Jiang B, Byrne J, Casadei B, Chowienczyk P, Shah AM. Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo. Circulation 2009;119:2656-2662.
15. Penny WF, Rockman H, Long J, Bhargava V, Carrigan K, Ibriham A, Shabetai R, Ross J Jr, Peterson KL. Heterogeneity of vasomotor response to acetylcholine along the human coronary artery. J Am Coll Cardiol 1995;25:1046-1055.
16. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, DeFalco RA, Leon MB. Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions. Circulation 1996;93:924-931.
17. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497. (Pubitemid 20055957)
18. Schindler TH, Nitzsche EU, Olschewski M, Magosaki N, Mix M, Prior JO, Facta AD, Solzbach U, Just H, Schelbert HR. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation 2004; 110:1069-1075. (Pubitemid 39319004)
19. Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS, Lerman LO, Lerman A. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 2007;115:2621-2627. (Pubitemid 46791360)
20. Molenaar P, Malta E, Jones CR, Buxton BF, Summers RJ. Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein. Br J Pharmacol 1988;95:225-233.
21. Rubanyi G, Vanhoutte PM. Endothelium-removal decreases relaxations of canine coronary arteries caused by beta-adrenergic agonists and adenosine. J Cardiovasc Pharmacol 1985;7:139-144. (Pubitemid 15162256)
22. Gray DW, Marshall I. Novel signal transduction pathway mediating endotheliumdependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol 1992;107:684-690.
23. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation 1997;95:2293-2297. (Pubitemid 27191007)
24. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, van der Arend BJ, Shu YE, MacKay LS,Webb DJ, Cockcroft JR. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002;22:147-152. (Pubitemid 34076246)
25. Whalen EJ, Johnson AK, Lewis SJ. Beta-adrenoceptor dysfunction after inhibition of NO synthesis. Hypertension 2000;36:376-382.
26. Stein CM, Nelson R, Deegan R, He H, Inagami T, Frazer M, Badr KF, Wood M, Wood AJ. Tachyphylaxis of human forearm vascular responses does not occur rapidly after exposure to isoproterenol. Hypertension 1995;25:1294-1300.
27. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonistmediated vascular desensitization. N Engl J Med 2001;345:1030-1035.
28. Graves J, Poston L. Beta-adrenoceptor agonist mediated relaxation of rat isolated resistance arteries: a role for the endothelium and nitric oxide. Br J Pharmacol 1993;108:631-637. (Pubitemid 23067928)
29. Toyoshima H, Nasa Y, Hashizume Y, Koseki Y, Isayama Y, Kohsaka Y, Yamada T, Takeo S. Modulation of cAMP-mediated vasorelaxation by endothelial nitric oxide and basal cGMP in vascular smooth muscle. J Cardiovasc Pharmacol 1998;32: 543-551. (Pubitemid 28440955)
30. Parent R, al-Obaidi M, Lavallee M. Nitric oxide formation contributes to beta-adrenergic dilation of resistance coronary vessels in conscious dogs. Circ Res 1993;73:241-251. (Pubitemid 23212104)
31. Gardiner SM, Kemp PA, Bennett T. Effects of NG-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5′-N- ethylcarboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol 1991;103:1725-1732.
32. Sun D, Huang A, Mital S, Kichuk MR, Marboe CC, Addonizio LJ, Michler RE, Koller A, Hintze TH, Kaley G. Norepinephrine elicits beta2-receptor-mediated dilation of isolated human coronary arterioles. Circulation 2002;106:550-555. (Pubitemid 34827703)
33. Newman CM, Maseri A, Hackett DR, el-Tamimi HM, Davies GJ. Response of angiographically normal and atherosclerotic left anterior descending coronary arteries to acetylcholine. Am J Cardiol 1990;66:1070-1076. (Pubitemid 20365359)
34. Hollenberg SM, Tamburro P, Johnson MR, Burns DE, Spokas D, Costanzo MR, Parrillo JE, Klein LW. Simultaneous intracoronary ultrasound and Doppler flow studies distinguish flow-mediated from receptor-mediated endothelial responses. Catheter Cardiovasc Interv 1999;46:282-288. (Pubitemid 29106943)
35. Miyata N, Yamaura H, Tsuchida K, Otomo S. Effects of CD-349 and 8-BrcGMP on isoproterenol-induced relaxation in rabbit aorta precontracted with endothelin-1. Am J Physiol 1992;263:H1113-H1118.
36. Graier WF, Kukovetz WR, Groschner K. Cyclic AMP enhances agonist-induced Ca2+ entry into endothelial cells by activation of potassium channels and membrane hyperpolarization. Biochem J 1993;291:263-267. (Pubitemid 23107780)
37. Baumgart D, Haude M, Gorge G, Liu F, Ge J, Grosse-Eggebrecht C, Erbel R, Heusch G. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999;99:2090-2097. (Pubitemid 29196791)
38. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, Indolfi C, Rimoldi O. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000;101:689-694. (Pubitemid 30094742)
39. Jensen BC, Swigart PM, Laden ME, DeMarco T, Hoopes C, Simpson PC. The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. J Am Coll Cardiol 2009;54:1137-1145.
40. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-2342.
41. Manginas A, Voudris V, Pavlides G, Karatasakis G, Athanassopoulos G, Cokkinos DV. Effect of plaque burden on coronary vasoreactivity in early atherosclerosis. Am J Cardiol 1998;81:401-406. (Pubitemid 28099528)
42. Nishimura RA, Lerman A, Chesebro JH, Ilstrup DM, Hodge DO, Higano ST, Holmes DR Jr, Tajik AJ. Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound. J Am Coll Cardiol 1995;26:41-49.
43. Schachinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo. Importance of baseline vasomotor tone in atherosclerosis. Circulation 1995;92:2087-2094.
44. Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J 2009;73: 394-403.